Fulminant progression of demyelinating disease after valproate-induced encephalopathy. Neurology 1998 Jul;51(1):292-5
Date
07/23/1998Pubmed ID
9674826DOI
10.1212/wnl.51.1.292Scopus ID
2-s2.0-0031868351 (requires institutional sign-in at Scopus site) 28 CitationsAbstract
We report the clinical, radiologic, and pathologic features of a patient who had fulminant demyelinating disease and who experienced acute progression of his disease after an episode of valproate-induced hyperammonemic encephalopathy. The role hyperammonemia played in the progression of the demyelination is uncertain. This case raises concern of a possible risk with the use of valproic acid in the subset of patients with fulminant demyelinating disease.
Author List
Blindauer KA, Harrington G, Morris GL 3rd, Ho KCAuthor
Karen A. Blindauer MD Chief, Professor in the Neurology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAnticonvulsants
Brain Stem
Cerebral Cortex
Contraindications
Demyelinating Diseases
Encephalitis
Humans
Male
Valproic Acid









